INSIGHTS ON CLINICAL TRIAL DESIGN
-
![GettyImages-2025692197_diabetic]( "Metabolic Disorders Clinical Trial Case Study")
Metabolic Disorders Clinical Trial Case StudyCheck out this case study to learn how partnering with an accomplished contract research organization is essential in the complex and dynamic field of metabolic drug development.
-
![diabetic-clinical-research-GettyImages-1280028815]( "Phase 1 Trial In Painful Diabetic Peripheral Neuropathy")
Phase 1 Trial In Painful Diabetic Peripheral NeuropathyA complex Phase 1 neuropathy study with overnight stays achieved full enrollment and retention through careful planning, strong participant engagement, and disciplined operational execution.
-
![Castor Product Spotlight New On-site ePRO]( "On-site ePRO Solutions For Flexible Data Collection Across Devices")
On-site ePRO Solutions For Flexible Data Collection Across DevicesOptimize flexible electronic patient-reported outcomes that allow participants to switch between site-owned devices, personal hardware, and remote completion.
-
![GLP-1 agonist injector pen, medical measuring tape-GettyImages-2226642622]( "Investigator Perspectives On What Matters In Obesity And GLP-1 Studies")
Investigator Perspectives On What Matters In Obesity And GLP-1 StudiesRetention, body composition, maintenance therapy, amylin combinations, and behavioral support are reshaping obesity trials. Learn how sponsors can reduce dropout risk and strengthen clinical data.
-
Outlook Good For 7 Drugs Up For Q3 Review8/15/2024
A total of 24 drugs, devices, diagnostics, and deals are expected to progress in the third quarter of 2024, including approval applications for 17 drugs. The estimated overall likelihood of approval is 90% or higher for seven of those drugs, including revumenib for acute myelogenous leukemia and KarXT for schizophrenia.
-
RTSM Misalignment Hiding In Your Clinical Trial Protocol5/13/2026
Unclear protocol details can quickly create problems across a clinical trial, but bringing in experienced systems thinkers early to identify gaps before they create downstream issues can help.
-
The Patient Recruitment Shift: Navigating Disruption, Delivering Precision3/27/2025
Explore the four macro trends reshaping the recruitment space in 2025—each grounded in emerging data, technology, and behavior shifts.
-
How Protocol Design Decisions Shape Recruitment, Data Quality & Study Startup6/29/2026
Protocol design directly affects recruitment, data quality, and startup speed. Clear workflows, streamlined criteria, and early alignment reduce delays, amendments, and improve reliable study execution.
-
Assessing Diversity In Early-Phase Clinical Trials In A Rapidly Changing Regulatory Environment5/5/2025
Learn more about structuring early-phase trials to address population variation and the contributing factors to safe drug administration, both of which are essential to a drug development plan.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![GettyImages-2161842577-business-professional-laptop-office-table]( "Overcome Biosafety Challenges With An Innovative IBC")
Simplify biosafety oversight and accelerate study startup with expert guidance that ensures NIH compliance while protecting researchers, communities, and the environment.
-
![GettyImages- 1254443202 medical writing]( "Medical Writing Services To Support Every Submission Milestone")
Ensure accurate, compliant, and impactful documentation with Altasciences' experienced medical writers and regulatory experts.
-
![Patient- doctor- GettyImages-2155775525]( "Therapeutic Experience: Supporting Recruitment And Retention")
CSS offers customized patient recruitment and retention solutions across the globe, ensuring successful enrollment for clinical trials across various therapeutic areas.
-
![GettyImages-953449116 clinical trial oversight]( "Smarter Oversight, Earlier Action")
When risk-based oversight is reduced to a compliance checkbox, critical signals can be missed and escalate into systemic issues.
-
![Eye Drop iStock-1182318206]( "Comprehensive Services For Ophthalmology Drug Development")
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market.
